HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Lineage Cell Therapeutics (LCTX) with a maintained price target of $7.
May 06, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Lineage Cell Therapeutics with a $7 price target.
The reaffirmation of a Buy rating and a $7 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on LCTX's stock price. Analyst ratings, especially those that are maintained or upgraded, tend to influence investor perception and can lead to increased buying activity.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100